Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

IV iron sucrose vs oral iron

Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients

It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 3.07 [0.13, 73.32]
1 study · 91 participants
Very low

IV iron isomaltoside vs oral iron

Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients

It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 4.02 [0.51, 31.73]
1 study · 338 participants
Very low

Oral ferric maltol vs oral placebo

Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients

It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 1 [0.15, 6.88]
1 study · 128 participants
Very low

Oral ferric maltol vs IV ferric carboxymaltose

Serious adverse events (12 weeks) · IBD patients

It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 2.95 [0.98, 8.91]
1 study · 252 participants
Very low

IV ferric carboxymaltose vs oral iron

Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients

It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 8.81 [0.52, 149.07]
1 study · 200 participants
Very low